Indegene
547.45
+1.00(+0.18%)
Market Cap₹13,142.52 Cr
PE Ratio31.50
IndustryHealthcare
Company Performance:
1D+0.18%
1M-4.73%
6M-8.71%
1Y-10.29%
5Y-4.11%
View Company Insightsright
More news about Indegene
23Jul 25
Indegene Limited Discloses Inadvertent Omission in Spanish Subsidiary Acquisition
Indegene Limited has provided additional details about its acquisition of Climacreative Spain S.L.U, a shelf company, through its wholly-owned subsidiary Indegene Ireland Limited. The acquisition, completed on November 19, 2024, for €5,500, was aimed at establishing a presence in Spain. The company acknowledged an inadvertent delay in disclosing this information and emphasized that the acquired entity had no prior business operations or turnover. The Spanish subsidiary has since been renamed Indegene Spain S.L.U.
22Jul 25
Indegene Limited Director Neeraj Bharadwaj Resigns Following Investor Exit
Indegene Limited, a healthcare technology company, has announced the resignation of Mr. Neeraj Bharadwaj from his position as Non-Executive, Non-Independent Director. The resignation follows CA Dawn Investments' exit from the company, as Mr. Bharadwaj was their representative on the board. The company has complied with SEBI regulations by promptly informing the stock exchanges about this change.
11Jul 25
Indegene Unveils NEXT: A GenAI-Powered Medical Writing Automation Platform
Indegene has introduced NEXT Medical Writing Automation, a platform combining medical writing expertise with generative AI technology. The tool aims to streamline medical writing workflows across clinical development and regulatory submissions. It integrates with existing systems, boosts efficiency through automated scheduling and task assignments, and maintains compliance. The platform is powered by Indegene's Cortex AI engine and is designed to elevate the practice of medical writing by allowing writers to focus on strategic tasks while automating data and formatting processes.
13Jun 25
Indegene Ltd. Sees Significant Block Trade Worth ₹106.63 Crore on NSE
A significant block trade of 1,804,900 shares of Indegene Ltd. was executed on the National Stock Exchange (NSE) at ₹590.80 per share, totaling ₹106.63 crore. This large transaction could indicate institutional investor activity or potential changes in ownership structure. Indegene Ltd. is a technology-led healthcare solutions provider offering digital transformation services for healthcare organizations.
05Jun 25
Indegene Shares Change Hands as Carlyle Exits; Major Funds Step In
Indegene Ltd experienced a significant change in its shareholding pattern through a block deal. Several prominent investment funds, including Abakkus Emerging Opportunities Fund, East Bridge Capital Master Fund, Societe Generale, Smallcap World Fund, and PI Opportunities AIF, acquired stakes in the company. Simultaneously, private equity firm Carlyle completely exited its 10.56% stake, selling shares at an average price of ₹591.00 per share.
05Jun 25
Indegene Shares See Major Acquisitions by Abakkus Fund and Societe Generale
Abakkus Emerging Opportunities Fund-1 purchased 12.10 lakh shares of Indegene at ₹591.48 per share through open market transactions. Simultaneously, Societe Generale acquired 18.80 lakh shares at ₹591.00 per share. The combined acquisition of 30.90 lakh shares by these two entities represents a substantial transaction volume for Indegene, potentially signaling investor confidence in the company's prospects.
04Jun 25
Carlyle Group Exits Indegene with Rs 1,447 Crore Stake Sale
Carlyle Group has divested its entire 10.2% stake in Indegene, a healthcare technology company, through open market operations for Rs 1,447.00 crore. The transaction involved selling over 2.44 crore shares at Rs 591.02 to Rs 591.84 per share. New investors, including Premji Invest, Capital Group, Societe Generale, Eastbridge Group, and Abakkus Asset Manager, have collectively acquired a 4.42% stake for approximately Rs 627.00 crore.
04Jun 25
Indegene Ltd: Carlyle Affiliate Offloads 10.5% Stake in Block Deal
CA Dawn Investments, an affiliate of Carlyle Group, sold a 10.5% equity stake in Indegene Ltd through block deals on June 4. The transaction involved approximately 2.44 crore shares at a floor price of ₹580.00 per share, potentially raising ₹1,420.00 crore. This follows a previous 4.7% stake sale in December, indicating a strategic realignment of ownership in the healthcare technology company.
04Jun 25
Indegene Shares Witness Massive Block Trade Worth ₹1,461 Crore on NSE
A significant block trade of approximately 24.67 million Indegene shares occurred on the National Stock Exchange. The shares were traded at ₹592.25 each, totaling ₹1,461.16 crore. This transaction represents a substantial portion of Indegene's outstanding shares and may indicate a shift in the company's ownership structure. The trade could impact investor confidence, market liquidity, and potentially influence short-term price movements of the stock.
03Jun 25
Carlyle Affiliate to Offload 10.2% Stake in Indegene Ltd for ₹1,420 Crore
CA Dawn Investments, an affiliate of Carlyle, plans to sell a 10.2% stake in Indegene Ltd through a block deal. The transaction involves 2.44 crore shares at a floor price of ₹580 per share, representing a 6.4% discount to the current market price. The deal, valued at approximately ₹1,420 crore, is being facilitated by Kotak and IIFL. This divestment could impact Indegene's ownership structure, market liquidity, and attract new institutional investors.
03Jun 25
CA Dawn to Offload 10.2% Stake in Indegene for ₹1,420 Crore
CA Dawn plans to divest a 10.2% stake in Indegene, a healthcare technology company, through a block deal. The floor price is set at ₹580.00 per share, with the deal valued at approximately ₹1,420.00 crore. This significant ownership change is expected to impact Indegene's shareholding pattern and potentially influence its stock price and trading volume.
29Apr 25
Indegene Reports Strong Q4 FY25 Results with 12.3% YoY Revenue Growth and 15.6% PAT Margin
Indegene Limited announced its Q4 and FY25 financial results, showing robust growth. Q4 revenue increased 12.3% YoY to ₹7,556.00 million, with PAT up 24.0% to ₹1,176.00 million. Full-year revenue grew 9.6% to ₹28,393.00 million, while PAT rose 20.8% to ₹4,067.00 million. The company maintained strong EBITDA margins and improved PAT margins. Segment-wise, Enterprise Medical Solutions showed the highest growth at 31.5% YoY. Indegene completed its IPO, raising ₹7,600.00 million, and announced a maiden dividend of ₹2.00 per share. The acquisition of MJL Communications Group Ltd is expected to enhance the company's capabilities.
28Apr 25
Indegene Reports Robust Q4 Performance: Net Profit Surges 24% YoY, Declares Final Dividend
Indegene Limited announced impressive Q4 FY2025 financial results, with consolidated net profit up 24% to ₹1.18 billion and revenue increasing 13% to ₹7.56 billion year-over-year. For the full fiscal year 2025, the company's revenue grew 9.6% to ₹28,393.00 million, while net profit surged 20.8% to ₹4,067.00 million. The Enterprise Medical Solutions segment showed significant growth of 33.6%. The company maintains a strong financial position with increased investments and has recommended a final dividend of ₹2.00 per equity share.
26Mar 25
Indegene's Irish Subsidiary Set to Acquire MJL Communications Group for £3.4 Million
Indegene Limited is set to acquire MJL Communications Group Ltd. and its subsidiary through its Irish subsidiary for up to £3.40 million. The all-cash deal, expected to complete by March 31, 2025, aims to strengthen Indegene's presence in Europe, particularly in the UK and EU markets. MJL Communications, a healthcare communications and advertising firm founded in 1982, reported provisional revenue of £1.92 million in 2024. This strategic move is anticipated to create synergies and support Indegene's long-term growth in the healthcare communications sector.
25Mar 25
Indegene's Irish Subsidiary to Acquire MJL Communications Group for £3.4 Million
Indegene Limited's Irish subsidiary is set to acquire MJL Communications Group Ltd. and its subsidiary for up to £3.4 million. The phased acquisition, expected to complete by March 31, 2025, aims to strengthen Indegene's European presence. MJL Group, a UK-based healthcare communications agency, specializes in brand creation, omnichannel campaigns, and healthcare initiatives. The all-cash deal includes potential earnouts and adjustments, aligning with Indegene's long-term growth strategy in the UK/EU market.
24Feb 25
Indegene Unveils Cortex: A Groundbreaking Generative AI Platform for Life Sciences
Indegene Limited has introduced Cortex, a generative AI platform tailored for the life sciences industry. Cortex incorporates 25+ years of industry expertise, offers flexible LLM integration, and enables multi-agent orchestration. The platform aims to streamline content supply chains, enhance medical writing, and accelerate MLR reviews. It promises faster turnaround times, better ROI, and improved accuracy compared to industry-agnostic platforms. Indegene's efforts in GenAI have been recognized by HFS Research and Everest Group.
Indegene
547.45
+1.00
(+0.18%)
1 Year Returns:-10.29%
Industry Peers
Syngene International
710.85
(-1.55%)
Indegene
547.45
(+0.18%)
Suven Life Sciences
274.99
(+2.11%)
Vimta Labs
708.60
(+7.98%)
Bilcare
69.99
(+1.02%)
Take Solutions
9.93
(-1.68%)
Adeshwar Meditex
18.00
(0.0%)
Vanta Bioscience
29.77
(0.0%)